Company intelligence
Eisai US
Breaking through in the therapeutic areas of oncology and neurology. View our community guidelines: https://bit.ly/3dkY
About Eisai US
At Eisai Inc., human health care (hhc) is our goal. We give our first thought to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to discover and develop innovative therapies to help address unmet medical needs. Eisai is a fully integrated pharmaceutical business that operates in two global business groups: oncology and neurology (dementia-related diseases and neurodegenerative diseases). Each group functions as an end-to-end global business with discovery, development, and marketing capabilities. Our U.S. headquarters, commercial and clinical development organizations are located in New Jersey; our discovery labs are in Massachusetts and Pennsylvania; and our global demand chain organization resides in Maryland and North Carolina. To learn more about Eisai Inc., please visit us at www.eisai.com/US. Comments and posts by users on this site are not created or controlled by Eisai Inc. and Eisai is not responsible for such content.
Verified activity
Signals from Eisai US
3 published signals
Research & Knowledge
Eisai US shared a new real-world meta-analysis in unresectable hepatocellular carcinoma at the ILCA26 conference.
Reported by Eisai US
Presence & Recognition
Eisai US Global CEO Haruo Naito was honored by Washington University School of Medicine in St. Louis for longstanding contributions to Alzheimer's disease research and healthcare.
Reported by Eisai US
Research & Knowledge
Eisai US announced a recent advancement to address unmet needs for early Alzheimer's disease.
Reported by Eisai US